Please type	9	nlus	sian	(+)	inside	this	hov	_
riease ivbe	a	pius	Sign	(T	molue	แแร	LUX.	

EN 8 TRADE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number	09/667,328			
Filing Date	September 21, 2000			
First Named Inventor	PACE et al.			
Group Art Unit	1616			
Examiner Name	S. Gollamudi			
Attorney Docket Number	401909/SKYEPHARMA			

			ι	J.S. PATENT DOCUMENTS		
		U.S. Patent Docume				
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
5	1	2803582		Cherney	8/20/1957	
	2	3137631		Soloway	6/16/1964	
	3	3216897		Krantz, Jr.	11/9/1965	
	4	3274063		Nieper et al.	9/20/1966	
	5	3594476		Merrill	7/20/1971	
	6	3715432		Merrill	2/6/1973	
	7	3755557		Jacobs	8/28/1973	
	8	3794476		Michalik et al.	2/26/1974	
	9	3937668		Zolle	2/10/1976	
	10	3960757		Morishita et al.	6/1/1976	
	11	3965255		Bloch et al.	6/22/1976	
	12	4016100		Suzuki et al.	4/5/1977	
	13	4053585		Allison et al.	10/11/1977	
	14	4056635		Glen et al.	11/1/1977	
	15	4073943		Wretlind et al.	2/14/1978	
	16	4078052		Papahadjopoulos	3/7/1978	
	17	4089801		Schneider	5/16/1978	
	18	4102806		Kondo et al.	7/25/1978	
	19	4107288		Oppenheim et al.	8/15/1978	
	20	4133874		Miller et al.	1/9/1979	
	21	4145410		Sears	3/20/1979	
	22	4147767	-	Yapel, Jr.	4/3/1979	
	23	4186183	····	Steck et al.	1/29/1980	
	24	4219548		Reller	8/26/1980	
	25	4235871		Papahadjopoulos et al.	11/25/1980	
	26	4241046		Papahadjopoulos et al.	12/23/1980	
	27	4271196		Schmidt	6/2/1981	
	28	4298594		Sears et al.	11/3/1981	
	29	4302459		Steck et al.	11/24/1981	
	30	4308166		Marchetti et al.	12/29/1981	
	31	4309421		Ghyczy et al.	1/5/1982	
	32	4316884		Álam et al.	2/23/1982	
	33	4320121	···	Sears	3/16/1982	
	34	4325871		Sasaki et al.	4/20/1982	
	3.5	4328222		Schmidt	5/4/1982	
	36	4329332		Couvreur et al.	5/11/1982	
	37	4331654		Morris	5/25/1982	
V	38	4332795	_	Ghyczy et al.	6/1/1982	
WW.	39	4332796		Los	6/1/1982	

Date Considered 6/26/03 **Examiner Signature**

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type	a olus	sion (+)	inside	this	box :	_

Sheet

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 of 8

Complete if Known				
Application Number	09/667,328			
Filing Date	September 21, 2000			
First Named Inventor	PACE et al.			
Group Art Unit	1616			
Examiner Name	S. Gollamudi			
Attorney Docket Number	401909/SKYEPHARMA			

			·	J.S. PATENT DOCUMENTS		
		U.S. Patent Docume	ent			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
للكو	40	4340594		Mizushima et al.	7/20/1982	
	41	4345588		Widder et al.	8/24/1982	
	42	4351831		Growdon et al.	9/28/1982	
	43	4356167		Kelly	10/26/1982	
	44	4369182		Ghyczy et al.	1/18/1983	
	45	4371516		Gregory et al.	2/1/1983	
	46	4378354		Ghyczy et al.	3/29/1983	
	47	4394372		Taylor	7/19/1983	
	48	4397846		Weiner et al.	8/9/1983	
	49	4411894		Schrank et al.	10/25/1983	
	50	4411933		Samejima et al.	10/25/1983	
	5 1	4421747		Ghyczy et al.	12/20/1983	
	52	4427649		Dingle et al.	1/24/1984	
	53	4432975		Libby	2/21/1984	
	54	4448765		Ash et al.	5/15/1984	
	55	4483847		Augart	11/20/1984	
	56	4485054		Mezei et al.	11/27/1984	· · · · · · · · · · · · · · · · · · ·
	57	4492720		Mosier	1/8/1985	
	58	4515736		Deamer	5/7/1985	
	59	4529561		Hunt et al.	7/16/1985	
	60	4532089		MacDonald	7/30/1985	
	61	4610868		Fountain et al.	9/9/1986	
	62	4613505		Mizushima et al.	9/23/1986	
	63	4629626		Miyata et al.	12/16/1986	· ·
	64	4675236		Ohkawara et al.	6/23/1987	
	65	4687762		Fukushima et al.	8/18/1987	
	66	4756910		Yagi et al.	7/12/1988	
	67	4758598		Gregory	7/19/1988	
	68	4761288		Mezei	8/2/1988	
	69	4762720		Jizomoto	8/9/1988	
	70	4766046		Abra et al.	8/23/1988	
	71	4776991		Farmer et al.	10/11/1988	
	72	4800079		Boyer	1/24/1989	
	73	4801455		List et al.	1/31/1989	
	74	4803070		Cantrell et al.	2/7/1989	
	7 5	4806350		Gerber	2/21/1989	
4	76	4806352		Cantrell	2/21/1989	
VEN	77	4826687 /		Nerome et al.	5/2/1989	_
	· '	1 1 1	\wedge	·		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Date Considered

6126103

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box —

Substitute for form 1449A/B/PTO

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of

Complete if Known				
Application Number	09/667,328			
Filing Date	September 21, 2000			
First Named Inventor	PACE et al.			
Group Art Unit	1616			
Examiner Name	S. Gollamudi			
Attorney Docket Number	401909/SKYEPHARMA			

			ī	J.S. PATENT DOCUMENTS		
		U.S. Patent Docume	ent			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
M	78	4839111		Huang	6/13/1989	
	79	4880634		Speiser	11/4/1989	
	80	4895726		Curtet et al.	1/23/1990	
	8 1	4961890		Boyer	10/9/1990	
	82	4963367		Ecanow	10/16/1990	
	83	4973465		Baurain et al.	11/27/1990	
	84	4990337		Kurihara et al.	2/5/1991	
	85	5030453		Lenk et al.	7/9/1991	
	86	5100591		Leclef et al.	3/31/1992	
	87	5164380		Carli et al.	11/17/1992	
	88	5169847		Nagy neé Kricsfalussy et al.	12/8/1992	
	89	5178878		Wehling et al.	1/12/1993	
	90	5179079		Hansen et al.	1/12/1993	
	91	5217707		Szabo et al.	6/8/1993	
	92	5246707		Haynes	9/21/1993	
	93	5272137		Blasé et al.	12/21/1993	
	94	5298262		Na et al.	3/29/1994	
	95	5302401		Liversidge et al.	4/12/1994	
	96	5304564		Tsuboi et al.	4/19/1994	
	97	5320906		Eley et al.	6/14/1994	
	98	5326552		Na et al.	7/5/1994	
	99	5336507		Na et al.	8/9/1994	
	100	5340564		Illig et al.	8/23/1994	
	101	5346702		Na et al.	9/13/1994	· · ·
	102	5352459		Hollister et al.	10/4/1994	
	103	5360593		Bapatla	11/1/1994	
	104	5364633		Hill et al.	11/15/1994	
	105	5389377		Chagnon et al.	2/14/1995	
	106	5399363		Liversidge et al.	3/21/1995	
1	107	5447710		Na et al.	9/5/1995	
	108	5470583		Na et al.	11/28/1995	
	109	5510118		Bosch et al.	4/23/1996	
	110	5527537		Dietl	6/18/1996	
	111	5545628		Deboeck et al.	8/13/1996	
	112	5552160		Liversidge et al.	9/3/1996	
1	113	5569448		Wong et al.	10/29/1996	
W	114	5576016/		Amselem et al.	11/19/1996	
		1001				

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Date Considered

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box	Please type	e a plus	sian (+) inside	this box	-
---	-------------	----------	---------	----------	----------	---

8

Substitute for form 1449A/B/PTO

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of

Complete if Known				
Application Number	09/667,328			
Filing Date	September 21, 2000			
First Named Inventor	PACE et al.			
Group Art Unit	1616			
Examiner Name	S. Gollamudi			
Attorney Docket Number	401909/SKYEPHARMA			

			Į.	J.S. PATENT DOCUMENTS	-	
Examiner		U.S. Patent Docume Application or	ent Kind		Date of	Filing Date If
Initials	Doc. No.	Patent Number	Code	Name of Patentee or Applicant	Publication	Appropriate
<u>ya</u>	115	5578325		Domb et al.	11/26/1996	
	116	5589455		Woo	12/31/1996	
	117	5603951		Woo	2/18/1997	
	118	5631023		Kearney et al.	5/20/1997	
	119	5637625		Haynes	6/10/1997	
	120	5639474		Woo	6/17/1997	
	121	5645856		Lacy et al.	7/8/1997	
	122	5660854		Haynes et al.	8/26/1997	
	123	5662932		Amselem et al.	9/2/1997	
	124	5663198		Reul et al.	9/2/1997	
	125	5676928		Klaveness et al.	10/14/1997	
	126	5776491		Allen, Jr. et al.	7/7/1998	
	127	5776495		Duclos et al.	7/7/1998	
	128	5827536		Laruelle	10/27/1998	
	129	5834025		de Garavilla et al.	11/10/1998	
	130	5851275		Amidon et al.	12/22/1998	
	131	5858410		. Muller et al.	1/12/1999	
	132	5880148		Edgar et al.	3/9/1999	
	133	5972366		Haynes et al.	10/26/1999	
	134	5976577		Green et al.	11/2/1999	
	135	6045829		Liversidge et al.	4/4/2000	
	136	6086376	_	Moussa et al.	7/11/2000	
	137	6096338		Lacy et al.	8/1/2000	
	138	6228399		Parikh et al.	5/8/2001	
	139	6267989		Liversidge et al.	7/31/2001	
	140	6270806		Liversidge et al.	8/7/2001	
	141	6337092		Khan et al.	1/8/2002	
	142	6387409		Khan et al.	5/14/2002	
	143	RE32393		Wretlind et al.	4/7/1987	
VAS.	144	RE35338		Haynes	9/24/1996	

Date Considered

6126103

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Sheet

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
5 of 8

TENT & TRADE

Complete if Known					
Application Number	09/667,328				
Filing Date	September 21, 2000				
First Named Inventor	PACE et al.				
Group Art Unit	1616				
Examiner Name	S. Gollamudi				
Attorney Docket Number	401909/SKYEPHARMA				

					N PATENT DOCUMENTS			
		F	oreign Patent Documen				Trans	lation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	145			1	Imperial Chemical Industries (see			-X *
		DE	2 513 797		Doc. No. 14)	10/9/1975		
~	146	Ę	2 938 807	<u> </u>	Green Cross Corp.	11/13/1980		-X ⁺
	147	DE			Dr. Rentschler Arzneimittel	12/19/1985		X ⁺
			3 421 468		GmbH & Co. (see Doc. No. 79)			
	148_	DE			DDS Drug Delivery Services (see	5/15/1996		X⁺
			4 440 337		Doc. No. 131)			
	149_	EP.	0.052.322		Gersonde, Klaus	5/26/1982		X [†]
	150	EP	0 193 208		Technicon Instruments Corp.	9/3/1986		
	151	EP	0 272 091		Vestar, Inc.	6/22/1988		
	152	EP			Fournier Industrie et Sante(see	8/30/1989		X ⁺
			0 330 532		Doc. No. 80)			
	153	EP			Yissum Research Development	10/10/1990		
***					Company of The Hebrew			
			0 391 369	ļ	University of Jerusalem			
,	154			ļ	Medgenix Group, S.A. (see Doc.			X⁺
		EP	0 418 153		No. 86)	3/20/1991		l
	155	EP	0 456 670		B. Braun Melsungen AG	11/21/1991	<u> </u>	X⁺
	156	EP_	0 456 764	-	B. Braun Melsungen AG	11/21/1991		X ⁺
X	157	EP	0 499 299		Sterling Winthrop Inc.	8/19/1992		
/_	158	EP	0 570 829	<u> </u>	Dr. Hans Dietl (see Doc. No. 110)	11/24/1993		_X ⁺
	159	EP	0 580 690		Sandoz Ltd.	2/2/1994		
MAY	160	EP	0 601 618	 	Sterling Winthrop Inc.	6/15/1994		
V	161	EP	0 602 700	 	Sterling Winthrop Inc.	6/22/1994		\vdash
VM	162	EP	0 687 172	 	Pharmacia AB	12/20/1995		
PG	163	EP.	0 007 172	 	Laboratoires Fournier S.C.A. (see	8/7/1996	<u> </u>	X⁺
_	103		0 724 877	 	Doc. No. 132)	0/7/1000		<u>├</u> ~
	164	EP.	0 757 911	 	CL Pharma. (see Doc. No. 128)	2/12/1997		X
	165	FR	2617.047	 	Sanofi et Laboratoires Fournier	12/30/1988		X ⁺
	166	GB	2,046,094	 	A. Nattermann & Cie	11/12/1980		
	167	HU	2,040,034	 	EGIS Gyógyszergyár (see Doc.	6/20/1995		-x+
_	197	- 10	211 580B	┼	No. 88)	0/20/1999		
	168_		211 0000	1	A. Nattermann & Cie (see Doc.			X [†]
	100	JP	1502590	┽───	No. 176)	11/12/1980		<u> ~ </u>
	169		1002000	1	A. Nattermann & Cie (see Doc.		1	X ⁺
_	103	JP.	55141407	 	No. 31)	11/5/1980	<u> </u>	! ^`
	170	JP	56167616		Green Cross Corp. (see Doc. No.	5/15/1980		X*
_	''	J	001111010		40)	3, 10, 1000		^
	171	JP.	60208910	==	A Nattermann & Cie	10/21/1985	<u> </u>	X ⁺
	<u> </u>	- 7	0 1 1		- Olo			

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* Note References that do not have an English abstract or translation have not been considered.

Date Considered

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this	s box
---	-------

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
6 of 8

1		Complete if Known	
ı	Application Number	09/667,328	
I	Filing Date	September 21, 2000	
I	First Named Inventor	PACE et al.	
	Group Art Unit	1616	
	Examiner Name	S. Gollamudi	
1	Attomey Docket Number	401909/SKYEPHARMA	

				FOREIG	N PATENT DOCUMENTS			
		F	oreign Patent Documen	ıt			Trans	lation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	172				Green Cross Corp. (see Doc. No.			X ⁺
		JP	83233915	<u> </u>	97)	10/21/1985		
	173				Liposome Technology, Inc. (see			X,
		JP-	63502117		Doc. No. 175)	8/13/1987		
- LA	174	wo	85/00011	1	University of Miami	1/3/1985		
y Cat	175	wo	87/04592		Liposome Technology, Inc.	8/13/1987		
	176	8	88/04924		Liposome Technology, inc.	7/14/1988		
	177	WO	91/04011	<u> </u>	Riker Laboratories, Inc.	4/4/1991		
Hard	178	wo	00/30616		RTP Pharma Inc.	6/2/2000		
~	-179 -	₩0	01/30372		Basf Aktiengesellschaft	5/3/2001		_X+
444	180	WO	92/18105		Sandoz Ltd.	10/29/1992		
· 1	181	wo	94/20072		Pharmacia AB	9/15/1994		
	182	WO	96/21439	j	Galephar P.R. Inc.	7/18/1996		
	183	WO	96/24332		Nanosystems L.L.C.	8/15/1996	, in the second	
	184	wo			Research Triangle	4/24/1997		
L L			97/14407		Pharmaceuticals			
	185	WO			Research Triangle	2/26/1998		
			98/07414	<u> </u>	Pharmaceuticals Ltd.			
	186	wo	98/41239		Nycomed Imaging AS	9/24/1998		
	187	8	99/49846		RTP Pharma Inc.	10/7/1999		
YAA	188	WO	99/61001		RTP Pharma Inc.	12/2/1999		

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Initials Doc. No. (book, magazine, journal, serial, symposiu		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
KW	189	ROSS et al., "Aqueous Solutions of Surface-Active Solutes", Collodial Systems and Interfaces, © 1988, pp. 148-151		
	190	SANDE et al., "Antimicrobial Agents: Antifungal and Antiviral Agents", <i>Practice of Infectious Diseases</i> , 2d Ed, 1985, pp. 1219-1222		
	191	BITTMAN, ROBERT, "Sterol-Polyene Antibiotic Complexation: Probe of Membrane Structure," <i>Lipids</i> , Vol. 13, No. 10, pp. 686-691 (1978).		
	192	MISHRA et al., "Scientifically Speaking: Novel Injectable Formulations of Water-Insoluble Drugs", Controlled Release Newsletter, Vol. 17, Issue 2, Jun 2000, pp. 21-30		
	193	BANGHAM et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids", <i>J. Mol. Biol.</i> , 1965, Vol.13, pp. 238-252		
X	194	HUANG et al., "Interaction of the N-terminus of Sterol Carrier Protein 2 with Membranes: Role of Membrane Curvature", <i>Biochem. J</i> , 1999, Vol. 8, pp. 593-603		

Examiner Signature Date Considered 6/26/03

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign
patent office in a counterpart foreign application dicating the degree of relevance found by the foreign office is being submitted in lieu of a concise
explanation of relevance under 37 CFR 1.98(a)(3).

Please	type a	phis	sign ((+)	inside	this	hov

Sheet

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
7 of

	Complete if Known	
Application Number	09/667,328	
Filing Date	September 21, 2000	
First Named Inventor	PACE et al.	
Group Art Unit	1616	
Examiner Name	S. Gollamudi	
Attorney Docket Number	401909/SKYEPHARMA	

	-	OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
M	195	GREGORIADIS, GREGORY, "The Carrier Potential of Liposomes in Biology and Medicine", New Engl. J. Med., 1976, Vol. 295, No. 13, pp. 704-710		
	196	CUDD et al., "Liposomes Injected Intravenously into Mice Associate with Liver Mitochondria, " Biochem. Biophys Acta, 1984, Vol. 774, pp. 169-180		
	197	BENZ et al., "Electrical Capacity of Black Lipid Films and of Lipid Bilayers Made from Monolayers", <i>Biochem. Biophys. Acta</i> , 1975, Vol. 394, pp. 323-334		
	198	GOODMAN and GILLMAN'S, "The Pharmacological Basis of Therapeutics," 7 th Ed., <i>MacMillan Publishing Co.</i> , New York,1985, Chap. 15, p. 312		
	199	CHERNEY, L.S., "Tetracaine Hydroiodide: A Long Lasting Local Anesthetic Agent for the Relief of Postoperative Pain", <i>Anesth. Analg.</i> ,1963, Vol. 42, No. 4, pp. 477-481		
	200	HAYNES et al., "Metal-Ligand Interactions in Organic Chemistry and Biochemistry", B. Pullman and N. Goldblum (eds.), part 2, 1977, pp. 189-212		
	201	HAYNES et al., "Ultra-Long Duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyflurane Microdroplets", <i>Anesthesiology</i> , 1985, Vol. 63, No. 5, pp. 490-499		
	202	HAYNES et al., "Ultra-Long Duration Local Anesthesia Produced by Intra-Dermal Injection of Lecithin-Coated Methoxyflurane Microdroplets", <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 1987, Vol. 14, pp. 293-294		
	203	KIRKPATRICK et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man," <i>Anesthesiology</i> , 1987, 67(3A): A254		
	204	GENNARO et al., "Sustained-Release Drug Therapy," Remington's Pharmaceutical Sciences, 17 th Ed.,1985, p. 1645		
	205	"Derived Diameters and Distribution Statistics," from an unknown web-site, 6 pages		
	206	"Getting Started", Man 0106, Issue 1.0, Jan. 1996, <i>Malvern Instruments Ltd.</i> , England, pp. 7.1-7.7		
	207	CHULIA et al., (Eds.), "Powder Technology and Pharmaceutical Processes", <i>Elsevier Science</i> , 1994, pp. 66-67.		
	208	HERBERT A. LEIBERMAN and LEON LACHMAN, Eds., <i>Pharmaceutical Dosage Forms</i> , Tablets, Vol. 1, 1980, p. 13		
X	209	MIYAJIMA, KOICHIRO, "Role of Saccharides for the Freeze-Thawing and Freeze- Drying of Liposome", <i>Advanced Drug Delivery Review</i> , Vol. 24, 1997, pp. 151-159		
	210	BUCHMULLER et al., "Cryopel: Ein neus Verfahren zum Pelletieren und Frosten Biologischer Substrate," Gas Aktuell, 35, 1989, pp. 10-13	<u> </u>	
W	211	WU et al., "Pharmacokinetics of Methoxyflurane After Its Intra-Dermal Injection as Lecithin-Coated Microdroplets, "Journal of Controlled Release, 1989, Vol. 9, pp. 1-12		
y.10	212	PACE et al., "Novel Injectable Formulations of Insoluble Drugs", <i>Pharmaceutical Technology</i> , Vol. 23, No. 3, Mar 1999, pp. 116-134		
6	213	ROMPP'S CHEMIE LEXIKON, 2 Aufl., Bd. 1,1950, Stichwort, "Emulsion"		X
	214	BERGMANN, LUDWIG, Der Ultraschall, 5 Aufl., Stuttgart, 1949, 672f, pp. 551-564		X
	215	LEHNINGER BIOCHEMISTRY, "The Molecular Basis of Cell Structure and Function", 1979, Chapter 10		
		1 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Date Considered

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please	type a	plus	sign	(+)	inside	this	box	-

Sheet

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

	Complete if Known
Application Number	09/667,328
Filing Date	September 21, 2000
First Named Inventor	PACE et al.
Group Art Unit	1616
Examiner Name	S. Gollamudi
Attorney Docket Number	401909/SKYEPHARMA

			OTHER - NON PATENT LITERATURE DOCUMENTS	_	
Exam	Examiner Initials Doc. No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		Trans	lation	
Initia	als L	DUC. NO.		Yes	No**
		216	GUZMAN et al., "Formation and Characterization of Cyclosporine-Loaded		
 Y &	⊿		Nanoparticles", 1088 J. Pharm. Sci 82, 1993, No. 5, pp. 498-502		
1		217	NAPPER, DONALD, H., "Polymeric Stabilizations of Colloidal Dispersions", 1983,		
1 1			book	İ	
		218	MULLER et al., "Emulsions and Nanosuspension", 1998, Chap. 9, p. 163	-	
		219	LOURENCO et al., "Steric Stabilization of Nanoparticles: Size and Surface		
			Properties", Int. J. of Pharm., Vol. 138, 1996, pp. 1-12		
		220	LUCKHAM, PAUL F., "The Physical Stability of Suspension Concentrates with		
1	1		Particular Reference to Pharmaceutical and Pesticide Formulations", Pestic. Sci.,	İ	
			1989, Vol. 25, pp. 25-34		
		221	CALVÖR et al., "Production of Microparticles by High-Pressure Homogenization",		
			Pharm. Development and Technology, 1998, 3(3), pp. 297-305		
		222	LAFUMA, FRANCOISE, "The Role of Water-Soluble Polymers at the Solid/Liquid		
			Interface in the Mechanisms of Flocculation/Stabilization of Aqueous Colloidal		
			Suspensions", <i>Polimery</i> , 1998, 43, nr 2, pp. 105-108		
\perp		223	Website http://userpage.fu-berlin.de/~kayser/nanosuspensionen.htm		
	1	224	MULLER et al., "Nanosuspensions for the I.V. Administration of Poorly Soluble Drugs-		
			Stability During Sterilization and Long-Term Storage", Proceed, Intern. Symp. Control.		
			Rel. Bioact. Mater., 22, 1995, pp. 574-575		
1		225	ZUIDAM et al., "Sterilization of Liposomes by Heat Treatment", Pharmaceutical	İ	
\perp			Research, Vol. 10, No. 11, 1993, pp. 1591-1596	 	
1,		226	FREITAS et al., "Spray Drying of Solid Lipid Nanoparticles (SLN™)", Elsevier	1	
V			Science, 1998, pp. 145-151	1	
		227	KAWASHIMA, YOSHIAKI, "Preparation of Powdered Phospholipid Nanospheres by		ł
			Spray Drying in an Aqueous System with Sugars", Chem. Pharm. Bull. 40 (7), 1992,		İ
			pp. 1911-1916		
				 	-
					<u> </u>
				-	L
					<u> </u>
-					
-	-+			†	
L					

Date Considered

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).